The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 28, Issue 5, 2005, Pages 461-466

  Kukanich, Butch ^a,c   Lascelles, B D X ^a   Aman, A M ^a   Mealey, K L ^b   Papich, M G ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; GLYCOPROTEIN P; KETOCONAZOLE; METHADONE; OMEPRAZOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENETIC CODE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; STOMACH ACID SECRETION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOGS; ENZYME INHIBITORS; FEMALE; GASTRIC ACID; H(+)-K(+)-EXCHANGING ATPASE; INJECTIONS, INTRAVENOUS; KETOCONAZOLE; MALE; METHADONE; OMEPRAZOLE; P-GLYCOPROTEIN;

ANIMALIA; CANIS FAMILIARIS;

EID: 27444436344     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2005.00681.x     Document Type: Article

References (41)

1. Ariano, R.E., Duke, P.C. & Sitar, D.S. (2001) Population pharmacokinetics of fentanyl in healthy volunteers. Journal of Clinical Pharmacology, 41, 757-763.
2. Benmebarek, M., Devaud, C., Gex-Fabry, M., Powell Golay, K., Brogli, C., Baumann, P., Gravier, B. & Eap, C.B. (2004) Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clinical Pharmacology and Therapeutics, 76, 55-63.
3. Bersenas, A.M.E., Mathews, K.A., Allen, D.G. & Conlon, P.D. (2005) Effects of ranitidine, famotidine, pantoprazole, and omeprazole on intragastric pH in dogs. American Journal of Veterinary Research, 66, 425-431.
4. Carlos, M.A., Du Souich, P., Carlos, R., Suarez, E., Lukas, J.C. & Calvo, R. (2002) Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. Journal of Pharmaceutical Sciences, 91, 1627-1638.
5. de Castro, J., Aguirre, C., Rodriguez-Sasiain, J.M., Gomez, E., Garrido, M.J. & Calvo, R. (1996) The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. Biopharmaceutics and Drug Disposition, 17, 551-563.
6. Codd, E.E., Shank, R.P., Schupsky, J.J. & Raffa, R.B. (1995) Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. Journal of Pharmacology and Experimental Therapeutics, 274, 1263-1270.
7. Dahlinger, J., Gregory, C. & Bea, J. (1998) Effect of ketoconazole on cyclosporine dose in healthy dogs. Veterinary Surgery, 27, 64-68.
8. Dale, O., Hoffer, C., Sheffels, P. & Kharasch, E.D. (2002) Disposition of nasal, intravenous, and oral methadone in healthy volunteers. Clinical Pharmacology and Therapeutics, 72, 536-545.
9. Davies, B. & Morris, T. (1993) Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 10, 1093-1095.
10. Eap, C.B., Buclin, T. & Baumann, P. (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clinical Pharmacokinetics, 41, 11 53-1193.
11. Foster, D.J., Somogyi, A.A. & Bochner, F. (1999) Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. British Journal of Clinical Pharmacology, 47, 403-412.
12. Garrett, E.R., Derendorf, H. & Mattha, A.G. (1985) Pharmacokinetics of morphine and its surrogates: VII. High-performance liquid chromatographic analyses and pharmacokinetics of methadone and its derived metabolites in dogs. Journal of Pharmaceutical Sciences, 74, 1203-1214.
13. Gibaldi, M. & Perrier, D. (1982) Pharmacokinetics, 2nd edn. pp. 1-494. Marcel Dekker Inc., New York, NY, USA.
14. German, A.L., Elliott, K.J. & Inturrisi, C.E. (1997) The D- and L-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neuroscience Letters, 223, 5-8.
15. Gourlay, G.K., Wilson, P.R. & Glynn, C.J. (1982) Pharmacodynamics and pharmacokinetics of methadone during the perioperative period. Anesthesiology, 57, 458-467.
16. Gourlay, G.K., Willis, R.J. & Lamberty, J. (1986) A double-blind comparison of the efficacy of methadone and morphine in postoperative pain control. Anesthesiology, 64, 322-327.
17. Hasselstrom, J. & Sawe, J. (1993) Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clinical Pharmacokinetics, 24, 344-354.
18. Hugnet, C., Bentjen, S.A. & Mealey, K.L. (2004) Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of collies from France. Journal of Veterinary Pharmacology and Therapeutics, 27, 227-229.
19. Kaunitz, J.D. & Akiba, Y. (2001) Integrated duodenal protective response to acid. Life Sciences, 69, 3073-3081.
20. Kharasch, F.D., Hoffer, C. & Whittington, D. (2004) The effect of quinidine, used as a probe for the involvement of p-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. British Journal of Clinical Pharmacology, 57, 600-610.
21. Ko, J.W., Sukhova, N., Thacker, D., Chen, P. & Flockhart, D.A. (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition, 25, 853-862.
22. KuKanich, B. & Papich, M.G. (2004) Pharmacokinetics of tramadol and the metabolite o-desmethyltramadol in dogs. Journal of Veterinary Pharmacology and Therapeutics, 27, 239-246.
23. KuKanich, B., Lascelles, B.D.X. & Papich, M.G. (2005a) Validation of a high-pressure liquid chromatography and fluorescence polarization immunoassay for the determination of methadone in canine plasma. Therapeutic Drug Monitoring, 27, 389-392.
24. KuKanich, B., Lascelles, B.D.X. & Papich, M.G. (2005b) Pharmacokinetics and pharmacodynamics of morphine in dogs following intravenous infusion and multiple intravenous doses. American Journal of Veterinary Research (in press).
25. KuKanich, B., Lascelles, B.D.X. & Papich, M.G. (2005e) Evaluation of a von Frey Device for pharmacodynamic modeling of morphine in dogs. American Journal of Veterinary Research, 66, 1616-1622.
26. Kuroha, M., Kuze, Y., Shimoda, M. & Kokue, E. (2002a) In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. American Journal of Veterinary Research, 63, 900-905.
27. Kuroha, M., Azumano, A., Kuze, Y., Shimoda, M. & Kokue, E. (2002b) Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. Drug Metabolism and Disposition, 30, 63-68.
28. Kyles, A.E., Papich, M. & Hardie, E.M. (1996) Disposition of transdermally administered fentanyl in dogs. American Journal of Veterinary Research, 57, 715-719.
29. Lin, J.H. (1995) Species similarities and differences in pharmacokinetics. Drug Metabolism and Disposition, 10, 1008-1021.
30. Martinez, M.N., Papich, M.G. & Riviere, J.E. (2004) Veterinary application of in vitro dissolution data and the biopharmaceutics classification system. Pharmacopeial Forum, 30, 2295-2303.
31. Mealey, K.L. (2004) Therapeutic implications of the MDR-1 gene. Journal of Veterinary Pharmacology and Therapeutics, 27, 257-264.
32. Mealey, K.L., Bentjen, S.A., Gay, J.M. & Cantor, G.H. (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics, 11, 727-733.
33. Mealey, K.L., Northrup, N.C. & Bentjen, S.A. (2003) Increased toxicity of p-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. Journal of the American Veterinary Medical Association, 223, 1434, 1453-1455.
34. Myre, S.A., Schoeder, T.J., Grund, V.R., Wandstrat, T.L., Nicely, P.G., Pesce, A.J. & First, M.R. (1991) Critical ketoconazole dosage range for ciclosporin clearance inhibition in the dog. Pharmacology, 43, 233-241.
35. Oda, Y. & Kharasch, E.D. (2001) Metabolism of methadone and levoalpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. The Journal of Pharmacology and Experimental Therapeutics, 298, 1021-1032.
36. Sartor, L.L., Bentjen, S.A., Trepanier, L. & Mealey, K.L. (2004) Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. Journal of Veterinary Internal Medicine, 1, 117-118.
37. Schlitt, S.C., Schroeter, L.M., Wilson, J.E. & Olsen, G.D. (1978) Methadone-induced respiratory depression in the dog: comparison of steady-state and rebreathing techniques and correlation with serum drug concentration. Journal of Pharmacology and Experimental Therapeutics, 207, 109-122.
38. Schmidt, N., Brune, K., Williams, K.M. & Geisslinger, G. (1994) Stereoselective pharmacokinetics of methadone in beagle dogs. Chirality, 6, 492-495.
39. Stanley, T.H., Liu, W.S., Webster, L.R. & Johansen, R.K. (1980) Haemodynamic effects of intravenous methadone anaesthesia in dogs. Canadian Anaesthetists' Society Journal, 27, 52-57.
40. Wang, J.S. & DeVane, C.L. (2003) Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metabolism and Disposition, 31, 742-747.
41. Ward, K.W., Stelman, G.J., Morgan, J.A., Zeigler, K.S., Azzarano, L.M., Kehler, J.R., McSurdy-Freed, J.E., Proksch, J.W. & Smith, B.R. (2004) Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics: II. Use of ketoconazole to identify p-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metabolism and Disposition, 32, 172-177.